Clinical oncology is going through a period of profound change. Targeted therapy, and more recently immunotherapy, have revolutionized the natural history and outcomes of many solid tumors. Clinical oncology is now indissoluble from molecular oncology, a rapidly evolving field. This profound transformation is the rationale for molecular tumor board (MTB) implementation. MTBs represent a resource for the development of precision oncology and clinical practice implementation is a complex and important challenge for the future of clinical and molecular oncology. Economic sustainability of genomic tests, access to drugs or clinical trials according to the MTB recommendation, and expanded use of existing anticancer drugs are required for MTBs to become a useful tool for the governance of precision oncology in the real world. This is an ongoing process, with establishment of MTBs the first step. Continuing to work in collaboration with scientific societies, MTBs are poised to become a homogeneous and well-structured reality that can make the care pathway of the patient with cancer more efficient, with the ultimate goal to offer personalized therapy based on the most advanced scientific knowledge.

1. Garraway, LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 31: 1806–1814.
Google Scholar | Crossref | Medline2. Danesi, R, Fogli, S, Indraccolo, S, et al. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of molecular tumor boards. ESMO Open 2021; 6: 100040.
Google Scholar | Crossref | Medline3. Luchini, C, Lawlor, RT, Milella, M, et al. Molecular tumor boards in clinical practice. Trends Cancer 2020; 6: 738–744.
Google Scholar | Crossref | Medline4. AIOM . Raccomandazioni 2020 sui Farmaci Agnostici, https://www.aiom.it/raccomandazioni-2020-sui-farmaci-agnostici/
Google Scholar5. Kato, S, Kim, KH, Lim, HJ, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun 2020; 11: 4965.
Google Scholar | Crossref | Medline6. van der Velden, DL, van Herpen, CML, van Laarhoven, HWM, et al. Molecular tumor boards: current practice and future needs. Ann Oncol 2017; 28: 3070–3075.
Google Scholar | Crossref | Medline7. AIOM . Raccomandazioni 2020 Tumor Board Molecolare, https://www.aiom.it/raccomandazioni-2020-tumor-board-molecolare/
Google Scholar8. Russo, A, Incorvaia, L, Del Re, M, et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC/IAP–SIBIoC–SIF Italian Scientific Societies, ESMO Open 2021; 6: 100164.
Google Scholar | Crossref | Medline9. AIOM . Raccomandazioni 2020 per l’esecuzione di Test Molecolari su Biopsia Liquida in Oncologia, https://www.aiom.it/raccomandazioni-2020-per-lesecuzione-di-test-molecolari-su-biopsia-liquida-in-oncologia/
Google Scholar10. Russo, A, Incorvaia, L, Malapelle, U, et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM–SIAPEC/IAP–SIBIoC–SIF Italian Scientific Societies. Crit Rev Oncol Hematol 2021; 165: 103436.
Google Scholar | Crossref | Medline11. Erdmann, J. All aboard: will molecular tumor boards help cancer patients? Nat Med 2015; 21: 655–656.
Google Scholar | Crossref | Medline12. Mosele, F, Remon, J, Mateo, J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2020;3 1: 1491–1505.
Google Scholar | Crossref13. Pishvaian, MJ, Blais, EM, Bender, RJ, et al. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMA Open 2019; 2: 505–515.
Google Scholar | Crossref